ArticleCancer research2020
Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Abstract readValidation Study
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].Magyar onkologia · 2025Guideline
- Performance of LFSPRO prediction in TP53 mutation status for prospectively collected probands.American journal of human genetics · 2026Article
- Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers.Nature communications · 2025Article
- Optimizing shared decision-making for risk-reducing mastectomy in women with Li-Fraumeni syndrome using patient-reported outcome measures.Scientific reports · 2025Article
- The persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors: a population-based analysis.Clinical and experimental medicine · 2025Article
- Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious GermlineJCO clinical cancer informatics · 2024Article
- LFSPROShiny: an interactive R/Shiny app for prediction and visualization of cancer risks in families with deleterious germlinemedRxiv : the preprint server for health sciences · 2023Article
- Risk, molecular subtype and prognosis of second primary breast cancer: an analysis based on first primary cancers.American journal of cancer research · 2023Article
- TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.Briefings in bioinformatics · 2022Article
- Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched byFrontiers in oncology · 2022Article
- A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.Genome research · 2020Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Seung Jun ShinDepartment of Statistics, Korea University, Seoul, South Korea.
Elissa B Dodd-EatonDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fan GaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jasmina BojadzievaDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jingxiao ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2461-4616
Xianhua KongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christopher I AmosDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-8540-7023
Jing NingDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5289-331X
Louise C StrongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6795-3744
Wenyi WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. wwang7@mdanderson.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTRANSCRIPTIONAL REGULATION OF WT-1P01CA034936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 1985 to 2010
$26.4MTranslating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Rayjean J. Hung · 2017 to 2026
$23.7MCoordinating Center: Molecular and Cellular Findings of Screen-Detected LesionsU01CA196386 · NCI · DARTMOUTH COLLEGE · PI AMOS, CHRISTOPHER I. · 2015 to 2020
$4.1MGenome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)R01CA186566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I., HASSAN, MANAL METWALLY · 2015 to 2019
$3.6MConsistent variable selection in p>>n settingsR01CA158113 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, VALEN EARL · 2011 to 2020
$2.8MStatistical methods for genomic analysis of heterogeneous tumorsR01CA183793 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2014 to 2018
$1.7MBioinformatics Tools for Genomic Analysis of Tumor and Stromal Pathways in CancerR01CA174206 · NCI · DANA-FARBER CANCER INST · PI PARMIGIANI, GIOVANNI LUIGI · 2013 to 2017
$1.7MStatistical methods and tools for cancer risk prediction in families with germline mutations in TP53R01CA239342 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2019 to 2022
$1.5MComparative Effectiveness of Cancer Research: Use Data from Multiple SourcesR01CA193878 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NING, JING · 2016 to 2019
$1.2MNCI NIH HHS P01 CA034936NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA158113NCI NIH HHS R01 CA174206NCI NIH HHS R01 CA183793NCI NIH HHS R01 CA186566NCI NIH HHS R01 CA193878NCI NIH HHS R01 CA239342NCI NIH HHS U01 CA196386NCI NIH HHS U19 CA203654
Abstract
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder associated with
Indexed as
Genetic Predisposition to DiseaseModels, GeneticPenetranceAdolescentAdultChildChild, PreschoolComputational BiologyDatasets as TopicFemaleFollow-Up StudiesGenetic CounselingGerm-Line MutationHeterozygoteHumansInfantTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.